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ABSTRACT 
The epithelium of the small intestine plays an important role in detoxification processes due to the presence of 
various xenobiotic-metabolizing enzymes from phase I and II, as well as transport proteins of the ATP-binding 
cassette superfamily. Exposure to xenobiotics induces the expression of these proteins in the small intestine, with 
multiple signaling pathways stimulated by exogenous compounds converging at individual gene promoters by 
mechanisms which have not been fully understood yet. In this context the promoter region of the CYP1A1 gene, 
encoding the phase I monooxygenase cytochrome P450 1A1, was analyzed by chromatin immunoprecipitation 
with regard to binding of xeno-sensing receptors following stimulation of Caco-2 cells with agonists of the aryl 
hydrocarbon receptor (AHR) and retinoid receptors. Histone acetylation in the regulatory region of CYP1A1 was 
enhanced by treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or all-trans retinoic acid (at-RA). Bind-
ing of retinoid-X-receptor (RXR) α to the promoter region was detected in response to at-RA, while AHR bound 
to the gene promoter following its activation by TCDD. Of note, enhanced RXRα binding was also detected after 
AHR stimulation, and increased AHR binding was observed after retinoid receptor activation by at-RA. Exposure 
of Caco-2 cells to mixtures of AHR and retinoid receptor agonists yielded synergistic induction of CYP1A1 
mRNA. In conclusion, the present data improve our knowledge on retinoic acid-dependent effects on CYP1A1 
expression and demonstrate unexpected mixture effects by cross-talk of the different receptors. 
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INTRODUCTION 
The epithelium of the small intestine is the 
first physical and biochemical barrier for 
compounds or contaminants which are in-
gested via the food. Resorbed small hydro-
philic xenobiotics are often excreted chemi-
cally unchanged via the bile or urine, whereas 
lipophilic substances have to be metabolized 
into excretable hydrophilic metabolites or 
conjugates. Phase I of this biotransformation 
process comprises oxidation or reduction re-
actions, and frequently polar functional 
groups such as hydroxyl (-OH), thiol (-SH), 
or amine (-NH2) groups are introduced into a 
target molecule. These reactions are primarily 
catalyzed by cytochrome P450 monooxygen-
ases (CYP). Some phase I metabolites require 
further modifications during phase II of xeno-
biotic metabolism, where metabolites are con-
jugated with endogenous hydrophilic mole-
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cules (for example glutathione, sulfate, or glu-
curonic acid) by enzymes such as glutathione 
S-transferases, sulfotransferases or UDP-glu-
curonosyltransferases. The elimination of 
phase I and/or phase II metabolites as well as 
unchanged drugs is mediated by an active 
transport accomplished by transport proteins 
belonging to the ATP-binding cassette (ABC) 
superfamily. For a review of the role of the 
intestinal epithelium in xenobiotic metabo-
lism, please refer to the review by Kaminsky 
and Zhang (2003).  
Many aspects of in vivo intestinal metab-
olism can be resembled in vitro by use of the 
human Caco-2 cell model (Buesen et al., 
2002, 2003; Ebert et al., 2005; Münzel et al., 
1999; Tamura et al., 2001). After differentia-
tion this tumor-derived cell line develops typ-
ical morphological characteristics of the po-
larized human small intestinal epithelium and 
expresses a wide variety of xenobiotic-metab-
olizing enzymes, as well as proteins of the 
ABC transporter superfamily (Boulenc et al., 
1992; Buesen et al., 2002; Meinl et al., 2008; 
Münzel et al., 1999; Peters et al., 1989; Schar-
mach et al., 2009; Tamura et al., 2001). 
Exposure by xenobiotics can modulate the 
expression of xenobiotic-metabolizing en-
zymes in the small intestine by various mech-
anisms, not all of which have been fully un-
derstood so far. Nuclear or cytosolic receptors 
which act as ligand-activated transcription 
factors upon binding of xenobiotics play a key 
role in the transcriptional regulation of genes 
related to drug metabolism, such as the aryl 
hydrocarbon receptor (AHR, also termed di-
oxin receptor), the constitutive androstane re-
ceptor, or the pregnane-X-receptor. Nuclear 
receptors are responsible for complex signal-
ing cross-talk and pharmacokinetic interac-
tions; for review see e.g. Plant and Aoubadi 
(2009). While several cellular consequences 
of activation of individual nuclear receptors 
have been analyzed in-depth, there are still 
knowledge gaps with regards to the actions 
exerted by other receptor types such as for ex-
ample the retinoid receptors. Elucidation of 
the regulation of drug metabolism under real-
life conditions is furthermore complicated by 
the fact that exposure actually occurs not to 
single chemical entities, but rather to complex 
mixtures of a multitude of compounds acting 
via different molecular modes of action, e.g. 
by activating different nuclear receptors 
which interact with respect to target gene reg-
ulation.  
The CYP1A1 gene, encoding the phase I 
enzyme cytochrome P450 1A1, is regulated 
by the AHR and widely recognized as model 
target gene of this receptor, which is activated 
by planar aromatic hydrocarbon, dioxins, and 
other chemically related compounds (Kawa-
jiri and Fujii-Kuriyama, 2007). Binding of the 
AHR to the CYP1A1 promoter has been sub-
ject to extensive research, e.g. see Kress et al. 
(1998). In addition, previous studies have 
demonstrated an influence of retinoids on 
CYP1A1 gene expression (Fallone et al., 
2004; Gambone et al., 2002; Jurima-Romet et 
al., 1997; Li et al., 1995; Ohno et al., 2012; 
Vecchini et al., 1995; Wanner et al., 1995). 
The presence of a retinoic acid response ele-
ment (RARE) in the CYP1A1 promoter region 
has also been demonstrated (Vecchini et al., 
1994).  
The aim of this study was therefore to fur-
ther analyze the transcriptional regulation of 
CYP1A1 in the human adenocarcinoma cell 
line Caco-2 by agonists of the AHR and the 
different retinoic acid receptors, alone or in 
combinations. It was hypothesized that recep-
tor crosstalk may be a key mechanism medi-
ating the occurrence of unexpected mixture 
effects which might deviate from simple ad-
dition of the effects caused by exposure to an 
individual compound activating only one sin-
gle type of receptor. The obtained data help in 
gaining a better understanding of the regula-
tion of xenobiotic detoxification by individual 
nuclear receptor agonists and their mixtures. 
 
MATERIAL AND METHODS 
Chemicals 
All-trans retinoic acid (at-RA) and 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
were purchased from Sigma-Aldrich (Tauf-
kirchen, Germany). The RAR agonist Am580 
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(CD336; [4-(5,6,7,8-tetrahydro-5,5,8,8,-tetra-
methyl-2-naphthalenylcarboxamido)benzoic 
acid]) and the RXR agonist CD2608 
(LG1069; (4-[1-(4,5,5,8,8-pentamethyl-5,6, 
7,8-tetrahydro-2-naphthyl)-ethyl] benzoic 
acid) were kindly provided by Dr. U. Reichert 
(CIRD-Galderma, Sophia-Antipolis, France). 
All other chemicals were purchased from 
Merck (Darmstadt, Germany) or Sigma-Al-
drich in the highest available purity. 
 
Cell culture 
The human colon adenocarcinoma cell 
line Caco-2 (ECACC, Porton Down, UK) was 
cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM; PAA Laboratories GmbH, 
Coelbe, Germany) supplemented with 10 % 
fetal calf serum, 100 IU/ml penicillin, and 
100 µg/ml streptomycin at 37 °C in a humid-
ified atmosphere of 5 % CO2. Cells from pas-
sages 29-40 were used for all experiments. 
Caco-2 cells were cultured in six-well plates 
until complete confluency and were further 
cultivated for 14 to 18 days in order to allow 
differentiation. For a recent detailed descrip-
tion of Caco-2 cell culture, please refer to 
Lichtenstein et al. (2017). Verification of suc-
cessful differentiation into enterocyte-like 
cells, which was also used as a verification of 
cell line identity for Caco-2 cells, has also 
been described in detail in the aforementioned 
previous publication (Lichtenstein et al., 
2017). 
 
Gene expression analysis 
Cells were treated with test compounds in 
concentrations as indicated in the figures. 
Compounds were always freshly dissolved in 
culture medium prior to treatment, from stock 
solutions prepared in dimethyl sulfoxide 
(DMSO). The final  DMSO  concentration in 
the treatment medium was 0.1 % (v/v). After 
24 h of incubation, the medium was removed, 
the cell monolayer was washed with ice-cold 
phosphate-buffered saline (PBS), and cells 
were harvested for subsequent RNA isolation. 
All compounds were used at non-cytotoxic 
concentrations, as determined by routine cy-
totoxicity testing, to ensure the absence of un-
specific effects caused by cellular stress. 
 
Preparation of RNA and real-time  
quantitative PCR analysis 
Total RNA was isolated using the RNeasy 
kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol including a 
DNase digestion step. The concentration and 
quality of the RNA was determined with a 
Nano Drop spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, USA). 2 µg 
of RNA were reverse transcribed by 200 U 
Moloney murine leukemia virus reverse tran-
scriptase (Promega, Heidelberg, Germany) 
using 100 pmol of oligo (dT)15 as primers (2 h 
at 42 °C). Real-time quantitative PCR was 
performed on a 7900HT real-time PCR cycler 
(Applied Biosystems, Darmstadt, Germany). 
Experiments were set up in triplicates con-
taining SYBR Green Mastermix (AbGene, 
Hamburg, Germany) and the respective pri-
mers (3 pmol per reaction). The primer se-
quences are available from Table 1. The ther-
mal cycling protocol comprised an initial de-
naturation step at 95 °C for 15 min, followed 
by 40 cycles of denaturation at 95 °C for 15 s, 
annealing and extension at 60 °C for 1 min, 
and a final extension at 60 °C for 15 min. The 
mRNA amount of CYP1A1 in each sample 
was normalized to its ACTB (encoding β-ac-
tin) content and then referred to vehicle con-
trols treated with the solvent DMSO only to 
obtain fold inductions. 
 
Table 1: Primer sequences used for real-time quantitative PCR 
Gene Forward primer Reverse primer 
ACTB 5’-CGTCCACCGCAAATGCTT-3’ 5’-GTTTTCTGCGCAAGTTAGGTTTTGT-3’
CYP1A1 5’-CACCATCCCCCACAGCAC-3’ 5’-ACAAAGACACAACGCCCCTT-3’ 
CYP1A1-3,000 5’-CGTTGCAATCAGCACTAAGG-3’ 5’-GATTGAAGGATCGGAATGGA-3’ 
neg. control 
(PAX5) 
5’-GTCAGGCCCTGCGACATC-3’ 5’-GCCAAGAATTTTGCTGACACAA-3’ 
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Chromatin immunoprecipitation 
For chromatin immunoprecipitation 
(ChIP) experiments differentiated Caco-2 
cells grown in 175 cm² cell culture flasks were 
used. Cells were treated for 1.5 h with TCDD, 
at-RA, or vehicle (DMSO), respectively. 
ChIP analyses were performed as described in 
detail by Ehlers et al. (2008), where a more 
detailed description of the experimental pro-
tocol can be found. Immunoprecipitation was 
carried out with antibodies directed against 
acetyl-histone H3 (H3-K9/K14, 06-599; Up-
state, Temecula, CA, USA), RXRα (D 20), 
RXRβ (C 20), and AHR (H 211) (all from 
Santa Cruz Biotechnology, Santa Cruz, CA, 
USA).  
A genomic region around 3,000 base pairs 
upstream of the transcription starting point of 
CYP1A1 was chosen for amplification follow-
ing ChIP. This region corresponds to the XRE 
cluster (i.e., a region containing multiple 
AHR-binding so-called xenobiotic response 
elements) in the CYP1A1 promoter (Figure 1). 
Subsequent to the digestion of RNA and pro-
teins, the enriched fragmented DNA was ana-
lyzed for the abundance of the promoter frag-
ments of interest, in comparison to the input 
control as well as control samples from sol-
vent-treated cells. Successful enrichment of 
immunoprecipitated DNA was demonstrated 
by real-time quantitative PCR via comparison 
with the amount of DNA in the input control. 
In addition, the second exon of the PAX5 gene 
located more than 13,000 base pairs down-
stream of its start codon was amplified as a 
negative control to demonstrate specificity of 
DNA enrichment. The DNA content of each 
sample was normalized to its ACTB content 
and then referred to input DNA to obtain fold 
enrichment. Primer sequences are shown in 
Table 1. 
 
Statistical analysis  
Statistical analyses were performed with 
SigmaPlot software. Statistical significance 
of differences between mean values were de-
termined by Student’s t-test or, for concentra-
tion-dependent studies, by one-way ANOVA 
followed by Dunnett’s post-hoc test. Statisti-
cally significant differences were assumed at 
p < 0.05. 
 
RESULTS 
Induction of CYP1A1 gene expression by 
AHR, RAR and RXR agonists 
First, Caco-2 cells were exposed to ago-
nists of different nuclear receptors to charac-
terize the impact of activation of these signal-
ing pathways on CYP1A1 mRNA expression 
(Figure 2). The real-time PCR data show that 
the model AHR agonist TCDD, as expected, 
drastically stimulated CYP1A1 gene expres-
sion. Exposure of cells to 50 nM TCDD in-
duced CYP1A1 gene expression by approxi-
mately 425-fold (Figure 2). Activation of 
RAR was initially accomplished by incuba-
tion of cells with increasing concentrations of 
at-RA. Only at concentrations of 10 µM or 
higher, a slight, but statistically significant ap-
proximately 3.5-fold increase in CYP1A1 ex-
pression was recorded, while lower concen-
trations of at-RA did not exert remarkable  
 
 
Figure 1: Schematic delineation of the CYP1A1 promoter with the XRE cluster containing known AHR 
binding sites, and with the genomic region used for amplification in the ChIP assays. 
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Figure 2: Real-time RT-PCR analysis of CYP1A1 mRNA expression in Caco-2 cells following stimula-
tion with different nuclear receptor agonists. Cells were treated with agonists of the AHR, the different 
retinoid receptors, or combinations of both. Combination of RXRα and AHR activation yields over-addi-
tive effects. Mean + SD (n ≥ 3 independent experiments) are shown. Statistical significance is indicated 
as follows: *, p < 0.05; **, p < 0.01. For detailed data from individual replicates, please refer to the 
Supplementary Data Table. 
 
 
effects (Figure 2). Activation of RAR with 
100 nM of the agonist Am580 did not signifi-
cantly affect CYP1A1 expression, whereas ac-
tivation of RXR by its ligand CD2608 led to 
a very slight, but significant approximately 2-
fold increase in CYP1A1 mRNA (Figure 2). 
 
Histone H3 acetylation status of the 
CYP1A1 promoter 
Both, the AHR and the retinoid receptors, 
act as ligand-dependent transcription factors 
which bind to the promoters of target genes 
and thereby regulate their transcription. This 
is generally associated with an increased his-
tone acetylation of the respective promoter re-
gion, and with increased binding of the acti-
vated transcription factors to their recognition 
sequences within the gene regulatory region 
of the DNA. The histone H3 acetylation status 
of the promoter of the CYP1A1 gene was 
therefore analyzed by chromatin immunopre-
cipitation (ChIP) assays (see also scheme in 
Figure 1). Differentiated Caco-2 cells were 
exposed to 50 nM TCDD for AHR activation 
or to 10 µM at-RA for RAR activation. Im-
munoprecipitations from nuclear cellular 
Caco-2 extracts were carried out with an anti-
body against acetylated histone H3 and a 
DNA region approximately 3,000 base pairs 
upstream of the transcription start was ampli-
fied from the precipitates by PCR.  
Figure 3A demonstrates the histone H3 
acetylation status in the promoter region of 
CYP1A1 (-3,000 bp upstream of the start co-
don) in Caco-2 cells. In control cells only 
treated with the solvent, histone H3 showed 
some constitutive acetylation in the promoter 
region of CYP1A1 even without xenobiotic 
treatment, while a substantial enhancement in 
the amplified DNA amount, corresponding to 
an increased acetylation of histone H3 in the 
respective genetic region, was recorded fol-
lowing treatment with both, at-RA and TCDD 
(Figure 3A). Histone H3 acetylation was not 
detected in the negative control, where a DNA 
region outside of any promoter region (i.e., 
the coding region of the gene PAX5; Figure 
3A) was amplified; this demonstrates the 
specificity of our assay. 
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Figure 3: Chromatin immunoprecipitation at the CYP1A1 promoter. Immunoprecipitation results with 
antibodies directed against acetylated histone H3 (H3Ac) (A), the AHR (B), RXRα (C), and RXRβ (D) 
are presented. The dashed line indicates the level at which no enrichment of the respective promoter 
region is present. Negative controls (amplification of the PAX5 coding region not responsive to the AHR 
or retinoid receptors) are shown as white bars for comparison. Mean + SD (n ≥ 4 independent experi-
ments) are shown. Statistical significance is indicated as follows: a, p < 0.05 vs. input control; b, p < 0.05 
vs. solvent control (i.e., treatment effect). For detailed data from individual replicates, please refer to the 
Supplementary Data Table. 
 
 
 
AHR, RXRα and RXRβ binding to the 
CYP1A1 gene promoter 
Increased histone H3 acetylation in the 
promoter region of CYP1A1 following xeno-
biotic treatment was observed (Figure 3A). 
This was plausible since histone acetylation is 
generally associated with gene activation. We 
now analyzed whether also the recruitment of 
the respective relevant transcription factors, 
namely AHR and retinoic acid receptors, to 
the same regions of the gene promoters would 
be detectable by ChIP assays. Activation of 
the AHR again was achieved by treatment 
with TCDD, while RAR activation was per-
formed using at-RA. ChIP analyses were car-
ried out with antibodies directed against the 
AHR, RXRα and RXRβ. In control cells 
treated with the solvent only, AHR and RXRβ 
were barely associated with the promoter of 
the CYP1A1 gene, whereas basal binding sig-
nificantly differing from non-antibody con-
trols was detected for RXRα (Figure 3). The 
known interaction between the AHR and the 
CYP1A1 promoter (-3,000 base pairs) was 
verified in samples from cells exposed to 
TCDD which showed massive binding of the 
AHR to this genetic region (Figure 3B). In ad-
dition, an increase in RXRα binding to the 
CYP1A1 promoter was also observed follow-
ing treatment of Caco-2 cells with TCDD 
(Figure 3C). No major impact of TCDD treat-
ment was observed with regard to the binding 
of RXRβ (Figure 2D). Cell treatment with at-
RA resulted in a statistically significant en-
richment of the RXRα-CYP1A1 promoter in-
teraction (Figure 3C), without affecting 
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RXRβ binding to the gene promoter (Figure 
3D). Interestingly, an increase in AHR bind-
ing to the CYP1A1 promoter was also visible 
following cell treatment with at-RA (Figure 
3B). Taken together these results indicate that 
individual treatment with either at-RA or 
TCDD might, to a certain degree, be able to 
assist the recruitment of both receptors, AHR 
and RXRα, to the CYP1A1 gene promoter, 
even without addition of an exogenous ligand 
of the second receptor. 
Experiments with at-RA concentrations in 
a range from 0.1 µM to 25 µM verified the 
generated data for the histone H3 acetylation 
at the CYP1A1 promoter and demonstrated 
the increased binding of AHR and RXRα (Ta-
ble 2). Moreover, substantial enrichment was 
now also seen for RXRβ, but only at the high-
est tested concentration of at-RA (Table 2). 
For histone H3 acetylation and AHR binding, 
lower concentrations of at-RA caused higher 
enrichment at the CYP1A1 promoter (Table 
2). Enrichment was again not detected in the 
negative control in these experiments (data 
not shown). 
 
AHR and retinoid receptor agonist mixture 
effects on CYP1A1 expression 
The data presented above indicate a cross-
talk between the different receptors. Recently 
it has been shown that the cross-talk of the 
AHR with Wnt/β-catenin signaling at the 
CYP1A1 promoter synergistically enhances 
the responses to AHR agonists (Schulthess et 
al., 2015). We were now interested whether 
similar effects might also be observed with 
AHR agonists and retinoids activating their 
respective receptors. Thus, in subsequent 
mixture experiments, the RXR agonists 
CD2608 and at-RA were combined with 
TCDD (Figure 2; right bars). The stimulation 
of both pathways, namely activation of the 
AHR with TCDD combined with an activa-
tion of the RAR/RXR-dependent signaling 
pathways by at-RA or CD2608, enhanced 
CYP1A1 mRNA expression by up to 870-
fold, which is significantly more than ex-
pected from the same concentration of the 
AHR agonist alone, and also significantly 
more than expected when additive effects of 
stimulation of the two individual signaling 
pathways is assumed. Thus a combined stim-
ulation of AHR- as well as RAR/RXR-de-
pendent transcription enhances the cellular 
levels of CYP1A1 mRNA in an over-additive 
manner (Figure 2). 
 
 
 
Table 2: ChIP analysis of CYP1A1 promoter binding of H3Ac, AHR, RXRα and RXRβ 
relative enrichment of CYP1A1 promoter region 
 referred to input DNA (input DNA = 1) 
concentration of 
at-RA 
immunoprecipitation with antibodies against: 
H3Ac AHR RXRα RXRβ 
0 µM 21 6 10 6 
0.1 µM 46 254 18 8 
1 µM 28 59 16 2 
25 µM 11 78 31 27 
Caco-2 cells were exposed to 0.1 µM, 1 µM or 25 µM at-RA or 0.1 % DMSO as solvent control. Fold 
enrichment of CYP1A1 DNA (region around -3,000 bp from the start codon; see Figure 1) was quantified 
by real-time quantitative PCR in comparison to input control DNA. Values in the table are means of 2 
replicates. For detailed data from individual replicates, please refer to the Supplementary Data Table. 
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DISCUSSION 
The connection between CYP1A1 expres-
sion and xenobiotic activation of the AHR has 
long been known and constitutes a rather 
well-investigated example of the transcrip-
tional regulation of a drug-metabolizing en-
zyme by xenobiotics via a ligand-activated re-
ceptor. However, additional factors which 
modulate CYP1A1 expression independently 
of the AHR and/or interact with AHR-de-
pendent signaling in the regulation of the 
CYP1A1 gene are much less understood (see 
also INTRODUCTION section and refer-
ences therein). 
Here, we incubated Caco-2 cells with ag-
onists of the AHR and different retinoid re-
ceptors. Our data demonstrate a pronounced 
induction following AHR activation. This 
corresponds well to the known inducibility of 
the gene by AHR agonists, e.g. see Kimura et 
al. (1986) and many further publications 
demonstrating that the CYP1A1 gene is regu-
lated via the AHR signaling pathway upon ac-
tivation of the receptor by compounds such as 
for example TCDD or 3-methylcholanthrene 
(Fernandez-Salguero et al., 1996; Prasch et 
al., 2003). With regards to the CYP1A1 pro-
moter, basal constitutive acetylation, along 
with pronounced hyper-acetylation upon ex-
posure of the cells to TCDD was observed. 
This goes well with data by Nakajima et al. 
(2003), who reported that the inhibition of 
histone deacetylases or of DNA methylation 
causes an increase in gene expression of 
CYP1A1 in HeLa cells.  
Data regarding the consequences of retin-
oid receptor activation on CYP1A1 expression 
are conflicting: it has been reported that at-
RA either down-regulates (Li et al., 1995; 
Wanner et al., 1995) or up-regulates (Vec-
chini et al., 1995) CYP1A1 gene expression in 
keratinocytes. In hepatocytes, at-RA had a 
weak inducing effect on CYP1A1 mRNA ex-
pression (Jurima-Romet et al., 1997), whereas 
opposing observations have been made in 
HepG2 hepatocarcinoma cells (Ohno et al., 
2012; Fallone et al., 2004). We now detected 
clearly inductive effects of at-RA on CYP1A1 
in human intestinal Caco-2 cells. The way by 
which retinoid receptors affect the CYP1A1 
gene promoter thus possibly differs between 
different cell types and/or is affected by fur-
ther variables such as the chosen cell culture 
conditions. Nonetheless, CYP1A1-inducing 
effects of at-RA, if observed in an in vitro sys-
tem, seem to be generally much less pro-
nounced than the corresponding effects ex-
erted by a potent AHR agonist. It should be 
noted in this context that at-RA is primarily 
an activator of RAR, not RXR. Nonetheless, 
it has been shown that at-RA binding to the 
RAR is the most important ligand needed for 
the activation of the RAR-RXR transcription 
factor heterodimer; e.g. see the review by 
Blomhoff and Blomhoff (2006). This war-
rants the analysis of RXR binding to the DNA 
in response to at-RA treatment. 
Interactions between the AHR and 
RAR/RXR have been described in the context 
of physiological organism development, but 
not for xenobiotic metabolism-related func-
tions of the receptors: for example, an im-
portant cross-talk occurs during the develop-
ment of the medaka fish (Hayashida et al., 
2004), where at-RA induces AhR gene ex-
pression which is necessary for the develop-
ment of blood vessels and bones in the fish 
embryos. Additionally, it was observed that 
rodent Cyp1a1 expression varies during cell 
differentiation (Reiners et al., 1992) and de-
velopmental stages (Giachelli et al., 1991), 
two processes strongly influenced by retin-
oid-dependent signaling. In our study the 
treatment of Caco-2 cells with TCDD resulted 
in the expected substantial increased binding 
of the AHR to the CYP1A1 promoter region, 
which contains known XREs (Kubota et al., 
1991; Kress et al., 1998). Of note, at-RA 
alone also caused an increased binding of the 
AHR to the CYP1A1 promoter. Vice versa, 
AHR activation by TCDD caused also bind-
ing of RXRα to the promoter, as did RAR ac-
tivation by at-RA. Data on transcription factor 
binding are corroborated by at-RA- and 
TCDD-induced hyperacetylation of the gene 
promoter. The present findings from ChIP 
analyses suggest a cross-talk between the re-
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ceptors at the CYP1A1 promoter. A step fur-
ther at the level of transcription, a very inter-
esting observation is that treatment of Caco-2 
cells with a mixture of the AHR agonist 
TCDD and different retinoid receptor ago-
nists resulted in a strongly over-additive ef-
fect on CYP1A1 mRNA expression. This un-
expected synergistic mixture effect points to-
wards a substantial cross-talk of the different 
receptors at the gene promoter or via their 
downstream signaling events. The CYP1A1 
promoter is known to by subject to synergistic 
activation processes, either by multiple AHR 
proteins binding to individual, cooperatively-
acting binding sites in the gene promoter, or 
by different transcription factors which also 
allow for synergistic effects in case both are 
activated by upstream signaling. Cooperativ-
ity at multiple AHR binding sites as well as 
the synergistic behavior of AHR- and β-
catenin-dependent signaling have recently 
been dissected in depth at the gene promoter 
level (Schulthess et al., 2015). The present 
data now point towards the existence of simi-
lar cross-talk mechanisms between the AHR 
and retinoid receptors. In fact, interactions be-
tween the AHR and RAR/RXR signaling 
pathway have been described previously: 
Gambone et al. (2002) showed that certain 
synthetic retinoids are also activating ligands 
of the AHR. Moreover, a retinoic acid re-
sponse element (RARE) has been identified in 
the CYP1A1 promoter (Vecchini et al., 1994), 
while the authors of the latter paper did not 
broach the issue of cross-talk between the dif-
ferent receptors. Of note, the RARE identified 
by Vecchini et al. (1994) is located approxi-
mately 1000 base pairs upstream of the tran-
scription start of the first exon of CYP1A1 and 
therefore not identical to the RXRα-interact-
ing genomic region recognized in our analyis 
(see scheme in Figure 1).  
The crosstalk of AHR and RXRα surely 
warrants deeper investigation in follow-up 
studies. These will help revealing the 
AHR/RXRα cross-talk in more detail, and 
will further add to our knowledge on the reg-
ulatory network influencing the activity of the 
AHR. The present data constitute an instruc-
tive example on how multiple exogenous 
compounds are capable of influencing cellu-
lar targets in a synergistic manner, thus ques-
tioning if a general assumption of a maxi-
mally additive behavior of individual foreign 
compounds in toxicology sufficiently protects 
from unwanted effects. 
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